Novo Nordisk repurchased a total of 2,975,000 B shares during the first quarter, while a total of 3,000 options covered by Novo Nordisk treasury shares were exercised.
This announcement is pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual.
Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For further company information please visit www.novonordisk.com
For further information please contact:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Elin K Hansen |
Peter Haahr |
|
Tel (direct): (+45) 4442 3450 |
Tel (direct): (+45) 4442 1207 |
|
|
|
|
|
Palle Holm Olesen |
|
|
Tel (direct): (+45) 4442 6175 |
|
|
|
|
|
Christian Kanstrup |
|
|
Tel (direct): (+45) 4443 7801 |
|
|
|
|
In North America: |
In North America: |
|
Susan T Jackson |
Investor Relations Office US |
|
Tel (direct): (+1) 609 919 7776 |
Tel (direct): (+1) 609 919 7846 |
Stock Exchange Announcement No 8 / 2003
